22 days out from this announcement. Hopefully the 4th and final cohort dosing for this trial, will start within the next two weeks.
It would be nice to see some clinical action from this third cohort when the data is released. Dual dosing areas at this greater dose amount might achieve that.
GBM has no SOC, and these patients have no other chance. Positive data from this or the final cohort may lead to a fast track pathway, even with the recent FDA changes to how that happens.
Market cap, even with the original shares now out of escrow, is low, so good news could get this party started.
Ann: Dosing complete in 3rd cohort of CHM 1101 (CLTX CAR T) trial, page-8
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $28.14K | 7.037M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 243067 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 14771167 | 22 |
View Market Depth
| Last trade - 15.39pm 20/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |